0.40135.69% ( -0.0242 )
Closed: Nov 6, 16:00:00 (EDT)Current ValuationThe current P/E ratio is -2.65, within the reasonable range, cheaper than 33.38% of the time in the past 5 years, and the industry ranks 320/606, the industry Median -1.77.
-2.65xP/E
$0.43Stock price
$-0.16Earnings per share
-2.65xP/E
Stock price$0.43Earnings per share$-0.16
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -5.55x
- Typical range
- -16.48x–-1.36x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
013263952
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GILDUSGilead Sciences | -53.82x | 161.61% | $207.84B |
MRNAUSModerna | -30.59x | 16.99% | $96.40B |
CSLLYUSCSL Limited | -25.97x | -- | $66.97B |
NTRAUSNatera | -272.60x | 5.57% | $52.43B |
RVMDUSRevolution Medicines | -20.36x | 61.94% | $38.08B |
ROIVUSRoivant Sciences | -99.35x | 146.69% | $26.45B |
INSMUSInsmed | -39.40x | 75.15% | $23.86B |
BNTXUSBioNTech SE | -12.74x | 21.80% | $21.57B |
BBIOUSBridgebio Pharma | -24.43x | 31.08% | $14.47B |
SMMTUSSummit Therapeutics | -13.59x | 20.06% | $11.32B |
BMRNUSBioMarin Pharma | -568.62x | 60.62% | $10.87B |
KYMRUSKymera Therapeutics | -30.49x | 8.45% | $10.65B |
PCVXUSVaxcyte | -8.49x | 47.91% | $9.75B |
MDGLUSMadrigal Pharma | -59.46x | 90.48% | $9.24B |
SYREUSSpyre Therapeutics | -38.02x | 44.63% | $8.52B |
IBRXUSImmunityBio | -8.55x | 151.32% | $8.49B |
ARWRUSArrowHead Pharma | -25.37x | 35,923.70% | $8.12B |
TWSTUSTwist Bioscience | -58.08x | 28.63% | $7.94B |
CYTKUSCytokinetics | -9.93x | 7.04% | $7.72B |
ALKSUSAlkermes | -21,288.25x | 133.86% | $7.47B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
